Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Shoushtari
    Shoushtari
  8. Cheung
    Cheung
  9. Voss
    Voss
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)
  7. Epidemiology and Biostatistics (153)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Surgery (123)
  10. Survivorship Research (120)
Search Within
Formats
  1. Journal Article (751)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (11)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Sandra D'Angelo (26)

More People

Years
  1. 2025 (40)
  2. 2024 (60)
  3. 2023 (44)
  4. 2022 (122)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (412)
  2. Breast Cancer Research (67)
  3. BMC Cancer (65)
  4. Genome Biology (47)
  5. Journal of Hematology & Oncology (43)
  6. Journal of Translational Medicine (35)

More Publications

Results (1092)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer
    Journal Article

    Kyi, C.; Doubrovina, E.; Zhou, Q.; Kravetz, S.; Iasonos, A.; Aghajanian, C.; Sabbatini, P.; Spriggs, D.; O'Reilly, R. J.; O'Cearbhaill, R. E.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
    Guidelines

    Greten, T. F.; Abou-Alfa, G. K.; Cheng, A. L.; Duffy, A. G.; El-Khoueiry, A. B.; Finn, R. S.; Galle, P. R.; Goyal, L.; He, A. R.; Kaseb, A. O.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
    Journal Article

    Lin, T. Y.; Park, J. A.; Long, A.; Guo, H. F.; Cheung, N. K. V.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Emergency room imaging in pediatric patients with cancer: Analysis of the spectrum and frequency of imaging modalities and findings in a tertiary cancer center and their relationship with survival
    Journal Article

    Woo, S.; Araji, A.; El Amine, M. A.; Gangai, N.; Acquafredda, E.; Price, A. P.; Trippett, T. M.; Hricak, H.; Vargas, H. A.; Behr, G. G.
    Cancer Imaging (2021)

    Fulltext@MSK | Save
  • Endovascular management of a large renal artery aneurysm: A case report and review of the literature
    Journal Article

    Zhu, A.; Connolly, P.; Hakimi, A. A.
    BMC Urology (2021)

    Fulltext@MSK | Save
  • Y chromosomal noncoding RNAs regulate autosomal gene expression via piRNAs in mouse testis
    Journal Article

    Reddy, H. M.; Bhattacharya, R.; Tiwari, S.; Mishra, K.; Annapurna, P.; Jehan, Z.; Praveena, N. M.; Alex, J. L.; Dhople, V. M.; Singh, L.; more...
    BMC Biology (2021)

    Fulltext@MSK | Save
  • First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
    Journal Article

    Piha-Paul, S. A.; Geva, R.; Tan, T. J.; Lim, D. W. T.; Hierro, C.; Doi, T.; Rahma, O.; Lesokhin, A.; Luke, J. J.; Otero, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): An open-label dose-finding and first-in-human study
    Journal Article

    Naing, A.; Thistlethwaite, F.; de Vries, E. G. E.; Eskens, F. A. L. M.; Uboha, N.; Ott, P. A.; LoRusso, P.; Garcia-Corbacho, J.; Boni, V.; Bendell, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): Primary and biomarker analyses of a phase II study
    Journal Article

    D'Angelo, S. P.; Lebbé, C.; Mortier, L.; Brohl, A. S.; Fazio, N.; Grob, J. J.; Prinzi, N.; Hanna, G. J.; Hassel, J. C.; Kiecker, F.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): A first-in-human, dose-finding study
    Journal Article

    Sanborn, R. E.; Hamid, O.; de Vries, E. G. E.; Ott, P. A.; Garcia-Corbacho, J.; Boni, V.; Bendell, J.; Autio, K. A.; Cho, D. C.; Plummer, R.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save